Pembrolizumab, an anti-programmed death receptor-1 (PD-1) therapy, is currently approved under the brand name Keytruda ® for other gynecological cancers, including cervical cancer and endometrial ...

Frequent cystoscopy for monitoring nonmuscle-invasive bladder cancer (NMIBC) is burdensome and costly, prompting a search for alternatives.

In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an ...